LCN2 and melanoma: As a few studies have demonstrated a higher risk of nonmelanoma skin cancers (NMSC) and melanoma in patients with psoriasis but no biomarkers predictive of evolution have been identified yet, our main objective was to evaluate if NGAL could be considered a biomarker for the development of skin cancers in psoriatic patients.